DAB2IP and neoplasm: The fact that molecules secreted by cancer cells downregulate DAB2IP in stromal cells, and that DAB2IP likely plays a tumor-suppressive role in the TME (discussed above), implicate that RNA-based therapeutics aimed at increasing DAB2IP levels may not need to reach the core of solid tumors to be clinically effective.